Scinai Immunotherapeutics (SCNI) Receivables - Net (2015 - 2026)

Scinai Immunotherapeutics (SCNI) has 12 years of Receivables - Net data on file, last reported at $150.0 million in Q1 2026.

• For the quarter ending Q1 2026, Receivables - Net changed N/A year-over-year to $150.0 million; the trailing twelve-month figure through Mar 2026 stood at $150.0 million (changed N/A YoY), and the FY2025 full-year result was $73.0 million, up 87851.81% from the prior year.
• Receivables - Net rose to $150.0 million in Q1 2026, from $73.0 million in the prior quarter.
• In the past five years, Receivables - Net ranged from a high of $150.0 million in Q1 2026 to a low of $83000.0 in Q4 2024.
• A 5-year average of $22.4 million and a median of $165500.0 in 2022 frame the typical range for Receivables - Net.
• Across the five-year window, Receivables - Net sank 99.99% in 2022 and surged 87851.81% in 2025, its largest moves.
• Tracing SCNI's Receivables - Net over 5 years: stood at $202000.0 in 2022, then decreased by 24.75% to $152000.0 in 2023, then slumped by 45.39% to $83000.0 in 2024, then surged by 87851.81% to $73.0 million in 2025, then soared by 105.48% to $150.0 million in 2026.
• Business Quant data shows SCNI's Receivables - Net at $150.0 million in Q1 2026, $73.0 million in Q4 2025, and $139000.0 in Q2 2025.